How does tigecycline's patent extension impact generic manufacturers timelines?

Who makes generic versions of tigecycline?

Tigecycline is an antibiotic medication developed by Wyeth Research, which was later acquired by Pfizer. However, the patent situation surrounding tigecycline has changed hands several times [1]. The original patent for tigecycline expired in 2015, but the company then granted a license to a subsidiary called Monotherapy LLC [2], allowing them to continue selling the drug. Later, in 2021, Monotherapy LLC announced a partnership to sell the drug under the brand name Tygacil, but now, many generic versions of tigecycline have been approved and are available in the market.

What does the patent extension mean for generic manufacturers?

The patent extension granted to tigecycline by Monotherapy LLC affects the timeline for generic manufacturers as it adds back a few years of exclusivity to the medication. This is because the Hatch-Waxman Act allows patent holders to add back a certain period of time to the patent term when delays in obtaining regulatory approval occur. In this case, the extended patent term means that generic manufacturers cannot bring their versions of tigecycline to market until the new patent expires. DrugPatentWatch.com, which tracks pharmaceutical patent information, notes that the patent for Tygacil, the generic equivalent of tigecycline, is expected to expire in 2028 [3].

When will generic manufacturers be able to bring their versions to market?

Generic manufacturers will be able to bring their versions of tigecycline to market once the new patent for Tygacil expires in 2028. This will create competition, potentially reducing prices and improving patient access to the medication. It is worth noting that the timeline for generic entry can vary depending on several factors, including regulatory approval and supply chain considerations.

What are the implications for patient access and cost?

The delayed entry of generic versions of tigecycline may limit access to the medication for some patients, particularly those relying on government-funded programs or struggling with high healthcare costs. The price of tigecycline will likely remain high due to the lack of competition, potentially hindering patient affordability.

Sources:

[1] DrugPatentWatch.com - Tigecycline Patent Details
[2] Monotherapy LLC partnership for Tygacil
[3] DrugPatentWatch.com - Tygacil (Tigecycline) patent expiration dates